Spero Therapeutics Q4 revenue nearly triples, swings to profit

Overview

• US biopharma firm's Q4 revenue nearly tripled yr/yr, driven by higher collaboration revenue

• Q4 net income swung to profit from loss a year earlier

• Company expects cash reserves to fund operations into 2028

Outlook

• Spero estimates cash and equivalents will fund operations into 2028

• Company continues to explore opportunities to expand its clinical-stage portfolio

Result Drivers

• COLLABORATION REVENUE - Co said Q4 revenue increase was mainly due to higher collaboration revenue from GSK and Pfizer agreements

• MILESTONE PAYMENT - Co received $25 mln milestone payment from GSK in Q1 2026 triggered by tebipenem HBr NDA resubmission

• LOWER R&D COSTS - Research and development expenses fell due to decreased clinical trial activity related to the PIVOT-PO trial

Company press release: ID:nGNX41Q7PX

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "hold"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Spero Therapeutics Inc is $4.00, about 66% above its March 25 closing price of $2.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.